Activation of *CLN1* and *CLN2* G₁ Cyclin Gene Expression by *BCK2*

CHARLES J. DI COMO,^{1,2} HOWARD CHANG,^{1†} AND KIM T. ARNDT^{1*}

Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724-2212,¹ and Program in Genetics,
State University of New York, Stony Brook, New York 11794²

Received 2 June 1994/Returned for modification 2 August 1994/Accepted 3 January 1995

The *Saccharomyces cerevisiae* CLN3 protein, a G₁ cyclin, positively regulates the expression of *CLN1* and *CLN2*, two additional G₁ cyclins whose expression during late G₁ is activated, in part, by the transcription factors SWI4 and SWI6. We isolated 12 complementation groups of mutants that require *CLN3*. The members of one of these complementation groups have mutations in the *BCK2* gene. In a wild-type *CLN3* genetic background, *bck2* mutants have a normal growth rate but have a larger cell size, are more sensitive to α -factor, and have a modest defect in the accumulation of *CLN1* and *CLN2* RNA. In the absence of *CLN3*, *bck2* mutations cause an extremely slow growth rate: the cells accumulate in late G₁ with very low levels of *CLN1* and *CLN2* RNA. The slow growth rate and long G₁ delay of *bck2 cln3* mutants are cured by heterologous expression of *CLN2*. Moreover, overexpression of *BCK2* induces very high levels of *CLN1*, *CLN2*, and *HCS26* RNAs. The results suggest that *BCK2* and *CLN3* provide parallel activation pathways for the expression of *CLN1* and *CLN2* during late G₁.

The *Saccharomyces cerevisiae* *CLN1*, *CLN2*, and *CLN3* genes encode G₁ cyclins that interact with the CDC28 protein to form complexes with kinase activity (8, 21, 29, 33, 40). A sufficient level of CLN/CDC28 kinase activity is required during the late G₁ stage of the cell cycle for the execution of Start. Prior to the execution of Start, nutrient limitation or the presence of mating pheromones can arrest the cells in G₁. Once a cell has executed Start, nutrient limitation and mating pheromones do not prevent cell cycle progression (until the following G₁), and the cells are committed to divide.

In early G₁, the cells have very low levels of *CLN1* and *CLN2* RNAs. During late G₁, the levels of *CLN1* and *CLN2* RNAs increase dramatically (42). A large fraction of the late G₁ transcription of *CLN1* and *CLN2* is activated by the SWI4 and SWI6 transcription factors, which bind as a complex to sites in the *CLN1* and *CLN2* promoters (3, 30, 31). In addition, expression of normal levels of *CLN1* and *CLN2* during late G₁ requires the function of the CDC28 kinase and the function of at least one of the three *CLN* genes (*CLN1*, *CLN2*, or *CLN3*) (11, 15). These results have suggested that the accumulation of *CLN1* and *CLN2* RNAs during late G₁ requires CLN-associated kinase activity. It is currently not known what substrate(s) requires phosphorylation by the CLN-associated kinase for *CLN1* and *CLN2* RNA accumulation during late G₁.

In addition to the *CDC28* and *CLN* genes, the *SIT4* serine/threonine protein phosphatase is also required for the normal accumulation of *CLN1* and *CLN2* RNAs during late G₁ (19, 37). By contrast, *SIT4* is not required for normal levels of *CLN3* RNA. During late G₁, the *SWI4* RNA levels increase dramatically and reach their peak just prior to or at the time when *CLN1* and *CLN2* RNA levels reach their peak (5, 19). The requirement for *SIT4* for the normal accumulation of *CLN1* and *CLN2* RNAs during late G₁ is at least partly due to the requirement for *SIT4* for the normal increase in *SWI4* RNA levels during late G₁ (19).

CLN3 can regulate the rate of accumulation of *CLN1* and *CLN2* RNAs (8, 11, 15, 29). The dominant *CLN3-1* and *CLN3-2* alleles encode hyperactive forms of *CLN3* that increase the rate of *CLN1* and *CLN2* RNA accumulation during late G₁. Such cells initiate Start at a smaller than normal critical cell volume and are relatively resistant to α -factor. By contrast, deletion of *CLN3* results in a slower than normal rate of accumulation of *CLN1* and *CLN2* RNAs during late G₁. The $\Delta cln3$ cells initiate Start at a larger than normal critical cell volume and are more sensitive to α -factor than are wild-type cells. Because the *CLN3* protein is unstable (9, 40), the levels of the *CLN3* protein might be sensitive to the rate of protein synthesis. Therefore, *CLN3* (along with possible additional factors) may set the timing of Start relative to the growth rate of the cell.

The *CLN3* gene is normally dispensable, and $\Delta cln3$ cells have a normal growth rate (8, 29). However, the defect in *CLN1* and *CLN2* RNA accumulation resulting from the absence of *CLN3* becomes apparent when a *cln3* mutation is combined with an additional mutation in a gene that also functions for normal *CLN1* and *CLN2* RNA accumulation. For instance, $\Delta swi4$ cells have a slow-growth phenotype that is primarily due to a defect in *CLN1* and *CLN2* RNA accumulation (30, 31). Combining a *swi4* mutation with a *cln3* mutation results in a very slow growth rate that is partially cured by high-copy-number *CLN2* (30) or cured by heterologous expression of *CLN2* (3a). Likewise, *sit4* mutants have a defect in *SWI4*, *CLN1*, and *CLN2* RNA accumulation. Combining a *sit4* mutation with a *cln3* mutation results in near lethality. The near lethality of *sit4 cln3* strains is due to a defect in *CLN2* (and probably *CLN1*) RNA accumulation because the synthetic growth rate defect is completely cured by expressing *CLN2* at near wild-type levels from a *SIT4*-independent promoter (19).

To identify possible targets of the *SIT4* phosphatase that function for the expression of *CLN1* and *CLN2*, we isolated mutants that (like *sit4* mutants) require *CLN3* for either viability or a normal growth rate. The members of one complementation group of these mutants have mutations in the *BCK2* gene. The *BCK2* gene was originally isolated as a gene that in high copy number can suppress the temperature-sensitive cell lysis defect of mutations in the protein kinase C pathway (24).

* Corresponding author. Mailing address: Cold Spring Harbor Laboratory, P.O. Box 100, Cold Spring Harbor, NY 11724-2212. Phone: (516) 367-8836. Fax: (516) 367-8369. Electronic mail address: arndt@cshl.org.

† Present address: Harvard University, Boston, MA 02139.

TABLE 1. Yeast strains used

Strain	Genotype	Source or reference
AY925	<i>MATa ura3-1 leu2-3,112 his3-11,15 trp1-1 ade2-1 ssd1-d2 can1-100</i>	W303 of R. Rothstein
CY279	<i>MATα Δsit4::HIS3 SSD1-v ura3 leu2 his3 trp1</i>	37
CY2446	<i>MATα Δcln3::HIS3 SSD1-v ura3-52 leu2 his3 trp1 ade2-101 ade3::HisG {CLN3/ADE3/YCp50}</i>	This study
CY2932	<i>MATa Δcln3::HIS3 SSD1-v ura3-52 leu2 his3 lys2 ade2-101 ade3::HisG {CLN3/ADE3/YCp50}</i>	This study
CY3182	<i>MATa/MATα Δmpk1::TRP1/- ura3-52/- leu2-3,112/- his4/- trp1-1/- can1'/can1'</i> homozygous diploid	24
CY3276	<i>MATa Δbck2::TRP1 SSD1-v ura3-52 leu2-3,112 his4 trp1-1 can'</i>	D. Levin
CY3317	<i>CY3276 {BCK2/YCp50}</i>	This study
CY3319	<i>CY3276 {YCp50}</i>	This study
CY3507	<i>AY925 {pGAL:BCK2/YCp50}</i>	This study
CY3510	<i>AY925 {YCp50/pGAL expression plasmid with no insert}</i>	This study
CY3557	<i>MATa ssd1-d ura3-52 leu2Δ1 his3Δ200 ade2-101 lys2-801 plus SCB-lacZ at HIS3 locus</i>	B. Andrews
CY3582	<i>MATa Δswi4::HIS3 in CY3557 background</i>	J. Ogas
CY3656	<i>MATa Δswi6::HIS3 in CY3557 background</i>	B. Andrews
CY3779	<i>MATα Δswi6::HIS3 ssd1-d ura3-52 leu2Δ1 his3Δ200 ade2-101 lys2-801 {2μm/URA3/MCB-lacZ}</i>	This study
CY3798	<i>MATα ssd1-d ura3-52 leu2Δ1 his3Δ200 ade2-101 lys2-801 {2μm/URA3/MCB-lacZ}</i>	This study
CY4271	<i>CY3507 plus Δcln2::TRP1</i>	This study
ΔY79	<i>MATa Δbck2::TRP1 pGAL:CLN3 (LEU2 marked, at CLN3 locus) ura3 leu2 his3 trp1 ade2 {YCp50}</i>	This study
ΔY80	<i>MATa Δbck2::TRP1 pGAL:CLN3 (LEU2 marked, at CLN3 locus) ura3 leu2 his3 trp1 ade2 {BCK2/YCp50}</i>	This study
263	<i>MATa ctr7-263 Δcln3::HIS3 SSD1-v ura3-52 leu2 his3 lys2 ade2-101 ade3::HisG {CLN3/ADE3/YCp50}</i>	This study

More recently, *BCK2* was isolated as a suppressor of a *cln1 cln2 cln3* strain (18, 20a). Epstein and Cross (18) found that *bck2* cells are dramatically impaired in their growth rate if they also lack *CLN3*. Moreover, these authors found that transcription of a *CLN2* reporter construct in cells arrested in G₁ because of the lack of *CLN* function (which gives low levels of *CLN2* RNA) is about 8.5-fold further reduced in *bck2* cells compared with *BCK2* cells. Here we show that, in the absence of *CLN3*, *BCK2* is required for *CLN1* and *CLN2* RNA accumulation during G₁. Moreover, overexpression of *BCK2* causes a large increase in the levels of *CLN1* and *CLN2* RNAs. Genetic interactions between *Δbck2*, *Δsit4*, and *Δcln3* mutations suggest a model whereby *BCK2* and *SIT4* function in a pathway that activates *CLN1* and *CLN2* expression in parallel with the *CLN3* pathway.

MATERIALS AND METHODS

Yeast strains and media. Yeast strains used are listed in Table 1. Yeast cells were grown on either YPD medium (1% yeast extract, 2% peptone, and 2% glucose) or synthetic complete (SC) medium (using, per liter, 0.2 g of leucine and 0.1 g of all other amino acids, 0.1 g of uracil, and 0.075 g of adenine, with the indicated carbon source) (35). For plasmid selection, the appropriate amino acid or uracil was omitted from the SC medium.

Isolation of *ctr* mutants. We prepared *MATa* and *MATα Δcln3::HIS3 SSD1-v ade2 ade3 ura3* strains that contained the *CLN3* gene on an *ADE3/URA3* centromere plasmid (CY2446 and CY2932; Table 1). When these cells contain the *CLN3/ADE3/URA3* plasmid, they accumulate a red pigment. Cells that have lost the *CLN3/ADE3/URA3* plasmid do not accumulate the red pigment. Strains CY2446 and CY2932, which do not require *CLN3*, form red colonies with many white sectors composed of cells that have lost the *CLN3/ADE3/URA3* plasmid. Also, when replica plated onto 5-fluoro-orotic acid (5-FOA) medium, which allows only *Ura*[−] cells to grow (4), these colonies give rise to a confluent patch of cells because they contain many *Ura*[−] segregants that are able to grow with a normal growth rate. If these starting strains also contain a mutation that causes *CLN3* to be essential, they will give rise to solid red colonies (all viable cells contain the *CLN3/ADE3/URA3* plasmid) where none of the cells are able to grow when replica plated onto 5-FOA medium. Strains CY2446 and CY2932 were mutagenized to 30% survival with ethyl methylsulfonate and plated for single colonies. From about 80,000 *MATa* and 80,000 *MATα* colonies, we obtained about 400 nonsectoring 5-FOA-negative (*Foa*[−]) colonies. Of these 400 putative *ctr* strains, 114 were placed into 12 complementation groups, using the sectoring and *Foa* phenotypes.

***CTR7* is the same gene as *BCK2*.** A *ctr7-263 pGAL:CLN3* strain was grown on galactose medium and transformed with a YCp50 library containing yeast genomic inserts (34). Two groups of plasmid complemented the slow-growth-rate

phenotype of the *ctr7-263 pGAL:CLN3* strain grown on glucose. One class of plasmid contained the wild-type *CLN3* gene. The other class of plasmid contained the authentic *CTR7* gene: a *LEU2* marker at the chromosomal locus corresponding to the cloned DNA was 100% linked to *ctr7* in 40 tetrads.

The location of the *CTR7* gene within the yeast DNA sequences was determined by subcloning and complementation analysis. A 3.3-kb *NsiI* fragment, which gave full *ctr7* complementation, contained sequences from about −550 to +2776 of the *BCK2* gene (24). *BCK2* coding sequences are from +1 to +2555, all numbers relative to the A of the *BCK2* putative ATG start codon. Frameshift mutations within *BCK2* coding sequences eliminated complementation.

Deletion alleles. The *Δcln3* mutation replaces *CLN3* DNA sequences between the *BstXI* and *EcoRI* sites (removes DNA sequences encoding amino acids 1 through 387, of 581 total amino acids) with either a 1.2-kb *HindIII URA3* fragment, a 2.2-kb *XhoI-SalI LEU2* fragment, or a 1.8-kb *BamHI HIS3* fragment. The *Δbck2::TRP1* mutation, obtained from D. Levin, removes DNA sequences coding for amino acids 338 through 693 of *BCK2* (of 851 total amino acids) and replaces them with two tandem copies of the *TRP1* gene (24). The isogenic wild-type, *Δswi4*, and *Δswi6* strains were obtained from J. Ogas and B. Andrews and are described in references 31 and 41.

Expression of *BCK2* from the *GAL1* promoter. Using oligonucleotide-directed mutagenesis, we created an *XbaI* restriction site 23 bp upstream of the A of the predicted *BCK2* ATG initiation codon. This *XbaI* site was used to place *BCK2* coding sequences under control of the *GAL1* promoter in either a YCp50 or a *LEU2/cen* expression plasmid.

***CLN2* promoter deletions.** The 2.5-kb *NruI-ClaI* fragment containing *CLN2* that encodes a *CLN2* protein with a triple hemagglutinin epitope tag at the carboxyl terminus, *CLN2C* in reference 39, was blunted into the *SmaI* and *AccI* sites of pUC118, yielding plasmid pCB1321. Oligonucleotide-directed mutagenesis was used to remove positions −499 to −403 for deletion CC, positions −409 to −318 for deletion DD, or positions −318 to −259 for deletion EE and replace them with a 6-bp *XhoI* site. *KpnI-PstI* fragments containing *CLN2* (for AA, CC, DD, or EE) or a *SphI-PstI* fragment containing *CLN2* (for BB) were blunted into the *HindIII* site of *LEU2/cen* plasmid pAB484 (constructed by replacing the *SalI-SmaI URA3*-containing fragment of YCp50 with the 2.2-kb *XhoI-SalI* fragment containing *LEU2*). For orientation 1, the *CLN2*-containing fragment is oriented so that the *CLN2* stop codon is closer to the *LEU2* gene, while for orientation 2, the *CLN2* promoter is closer to the *LEU2* gene.

Northern (RNA) analysis and probes. Total RNA was loaded onto a 1% agarose gel containing 6% formaldehyde, 0.02 M morpholinopropanesulfonic acid, 0.005 M sodium acetate, and 0.001 M EDTA (pH 7.0). The gels were blotted onto BioTrans nylon membranes. The probes were the 1.4-kb *ClaI-NotI* fragment of *CLN1*, the 0.75-kb *XhoI-HindIII* fragment of *CLN2*, the 0.6-kb *AluI* fragment of *ACT1*, the 2.2-kb *BamHI* fragment of *SWI4*, the 0.5-kb *EcoRI* fragment of *CLB5*, the 0.9-kb *EcoRI-BamHI* fragment of *HCS26*, the 2.4-kb *XbaI-NsiI* fragment of *MBP1*, the 2.7-kb *EcoRI* fragment of *RNR1*, the 1.36-kb *HindIII-EcoRI* fragment of *BCK2*, the 1.2-kb *HindIII* fragment of *URA3*, and the 2.0-kb *HindIII-XhoI* fragment of *CLB2*. The blots were washed twice (15 min each) at 24°C with 2× SSC (1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate)–0.1% sodium dodecyl sulfate (SDS) and then twice (15 min each) at 65°C with 0.1× SSC–0.1% SDS.

β -Galactosidase assays. To exponentially growing cells (on either SC lacking uracil [SC-uracil] 2% raffinose or SC-uracil-leucine 2% raffinose medium) at an optical density at 600 nm (OD₆₀₀) of 0.2 to 0.25, galactose was added to 2% (final concentration) at time zero. Cells were collected at the indicated times. Extracts were prepared by vortexing the cells in breaking buffer (0.1 M Tris [pH 8.0], 20% glycerol, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride) in the presence of glass beads and then centrifuging them for 10 min at 13,000 $\times$ g to remove cell debris. For the assays, 0.1 ml of extract was mixed with 0.9 ml of Z buffer (0.1 M NaPO₄ [pH 7.0], 0.01 M KCl, 1 mM MgSO₄, 4 mM 2-mercaptoethanol) and incubated at 28°C. After 5 min, 0.2 ml of *o*-nitrophenylgalactoside (Sigma N-1127; at 4 mg/ml in Z buffer) solution was added. The reactions were stopped by the addition of 0.5 ml of 1 M Na₂CO₃, and the A₄₂₀ was determined. β -Galactosidase units were calculated by the following formula: units = (A₄₂₀)(377.8)/(time, in minutes)(volume of extract in assay = 0.1 ml)(protein concentration of extract, in milligrams per milliliter). For each time point, the assays were performed on at least two separate equivalent cultures, and the average is reported.

RESULTS

Isolation of *BCK2* as a gene that is required in the absence of *CLN3*. Because $\Delta cln3$ strains have a wild-type growth rate, $\Delta cln3$ cells containing the *CLN3* gene on a centromere plasmid (a *CLN3/ADE3/URA3* plasmid) grow at about the same rate as $\Delta cln3$ cells. By contrast, if the $\Delta cln3$ {*CLN3/ADE3/URA3* plasmid} cells have a mutation (*ctr* [*cln* three requiring]) that causes *CLN3* to be required for a normal growth rate, cells that have lost the *CLN3* plasmid will be inviable or grow very slowly. Using the colony sectoring assay (23), we isolated about 400 *ctr* mutants (see Materials and Methods). Of the 400 putative *ctr* mutants, 114 were placed into 12 complementation groups. The remainder of the putative *ctr* mutants either complemented all *ctr* mutants of the opposite mating type (possible unique mutants), did not complement any of the *ctr* mutants of the opposite mating type (probably resulting from integration of the *CLN3/ADE3/URA3* plasmid), did not mate, or were unstable during storage and propagation.

Another copy of the *CLN3* gene (on a *LEU2/cen* plasmid) was introduced into representative *ctr1* through *ctr10* mutants. These mutants fell into one of three classes (Fig. 1A). For the first class, containing only groups 7, 9, and 10, the *CLN3/LEU2* plasmid transformants were able to grow at wild-type or near wild-type rates in the absence of the *CLN3/ADE3/URA3* plasmid (the strain background has a $\Delta cln3$ mutation). For the second class, groups 1, 2, 5, 6, and 8, the *CLN3/LEU2* plasmid transformants grew better if they also had the *CLN3/ADE3/URA3* plasmid, which suggests that these mutants grow better if they have two *CLN3* genes. For the third class, groups 3 and 4, the *CLN3/LEU2* plasmid transformants were able to grow only very poorly in the absence of the *CLN3/ADE3/URA3* plasmid.

The remainder of this report will focus on the *ctr7* mutants. The *CTR7* gene was cloned and found to be identical to the *BCK2* gene (see Materials and Methods). We will now refer to the *ctr7* mutants as *bck2* mutants. An extra copy of the wild-type *CLN2* gene did not increase the ability of the *bck2* mutants to grow in the absence of *CLN3* (Fig. 1B). By contrast, expression of *CLN2* coding sequences from the *Schizosaccharomyces pombe* *ADH* promoter (*S.p.ADH*, which expresses *CLN2* at levels similar to the *CLN2* levels in a wild-type strain [data not shown]) or from the *S. cerevisiae* *ADH* promoter (*S.c.ADH*, which gives 10- to 20-fold-higher levels of *CLN2* [data not shown]) allowed the *bck2* mutants to grow very well in the absence of *CLN3* (Fig. 1B). Related to these findings, Epstein and Cross (18) found that high-level expression of *CLN1* from the *GAL1* promoter can rescue the inviability of a *cln2 cln3 bck2* strain and that expression of *CLN2* coding sequences from the *CLN3* promoter can partially rescue a *cln1 cln3 bck2* strain. These findings suggest that *bck2* mutants

FIG. 1. Ability of *ctr* strains to grow in the absence of *CLN3*. (A) Summary of the ability of *ctr1* through *ctr10* strains to grow in the absence of *CLN3* after transformation with the indicated plasmid. We obtained 3 group 1, 14 group 2, 23 group 3, 13 group 4, 29 group 5, 8 group 6, 10 group 7, 5 group 8, 2 group 9, 3 group 10, 2 group 11, and 2 group 12 putative *ctr* mutants. +, full or near full wild-type ability; +/-, partial ability; -/+, slight ability; -, no or almost no ability to grow in the absence of *CLN3*. The ability of the strains to grow in the absence of *CLN3* was determined by both their sectoring and Foa phenotypes. The *ctr5* mutants may be *swi4* mutants because they are complemented by the wild-type *SWI4* gene. *SIT4* does not complement *ctr1* through *ctr10*. (B) Transformants of a *ctr7-263* $\Delta cln3$ {*CLN3/ADE3/URA3/cen* plasmid} strain (strain 263) with the indicated *LEU2/cen* plasmids were streaked for single colonies on a YPD plate and replica plated onto an SC plate containing 5-FOA (4), on which only Ura⁻ (that is, without the *CLN3*-containing *URA3/cen* plasmid) cells can grow. Growth is shown after 1.5 days at 30°C. The *S.p.ADH:CLN2*, *S.p.ADH:SWI4*, and *S.c.ADH:CLN2* plasmids were described in reference 19. An independent *ctr7* mutant gave equivalent results. In all cases, the ability to give sectorized colonies corresponded to the ability to grow on 5-FOA medium.

cannot grow (or grow very slowly) in the absence of *CLN3* is because of a defect in the expression of *CLN1* and *CLN2* from their normal promoters.

Like the *CLN1* and *CLN2* RNA levels, the *SWI4* RNA levels also peak in late G₁. The periodic expression of *SWI4* may be required for the normal expression of *CLN1* and *CLN2* (5). When the *bck2* mutants contained an extra copy of wild-type *SWI4*, there was a very slight increase in the ability to grow in the absence of *CLN3* (Fig. 1B). When *SWI4* coding sequences were transcribed from the *S.p.ADH* promoter (which gives about 5- to 10-fold-higher levels of *SWI4* RNA than from the wild-type promoter [data not shown]), the *bck2* mutants grew reasonably well in the absence of *CLN3* (Fig. 1B). Thus, overexpression of *SWI4* from a heterologous promoter can partially suppress the slow growth rate of *bck2 cln3* strains.

In the absence of *CLN3*, *BCK2* is required for normal *CLN1* and *CLN2* expression. To determine the effect of a null allele of *BCK2* on the ability to grow in the absence of *CLN3*, we obtained a $\Delta bck2::TRP1$ strain (CY3276) from D. Levin (24). When the $\Delta bck2$ strain was crossed to a $\Delta cln3$ strain, viable $\Delta bck2 \Delta cln3$ progeny were obtained, but they grew very slowly (data not shown). These findings contrast with those of Epstein and Cross (18), who reported that *bck2 cln3* spores are inviable. Perhaps strain background effects or their use of a *bck2*

disruption allele accounts for these differences. Two hours after glucose was added to a $\Delta bck2$ *pGAL:CLN3* strain growing on galactose medium (which repressed *pGAL:CLN3* expression), the culture became highly enriched in unbudded uninucleate cells with a 1n DNA content (data not shown), confirming the findings of Epstein and Cross (18). Moreover, for the $\Delta bck2$ *pGAL:CLN3* strain on glucose medium, heterologous expression of *CLN2* from the *S.p.ADH* promoter eliminated much of the long G_1 delay and restored a near wild-type growth rate, while heterologous expression of *CLN2* from the *S.c.ADH* promoter eliminated all of the G_1 delay and gave a wild-type growth rate (data not shown).

Previously, Epstein and Cross (18) showed that the RNA levels of a *CLN2* reporter in cells arrested in G_1 due to the lack of *CLN* function (conditions which give low *CLN2* expression because most *CLN2* transcription requires *CLN* function [11, 15]) is about 8.5-fold lower in *bck2* cells than in *BCK2* cells. To determine the rate and level of *CLN1* and *CLN2* RNA accumulation during G_1 in the absence *BCK2* and *CLN3* function in an otherwise wild-type cell, we used the procedure described in the legend to Fig. 2A. For the *BCK2 pGAL:CLN3* cells (effectively *BCK2 cln3*), the levels of *CLN1*, *CLN2*, *SWI4*, and *CLB5* RNAs increased and reached maximal levels at about 1 h after α -factor release (after which most of the cells formed a bud) (Fig. 2A). This rate of increase for the *CLN1*, *CLN2*, *SWI4*, and *CLB5* RNA levels is somewhat slower than for wild-type cells because of the absence of normal *CLN3* function. By contrast, when the $\Delta bck2$ *pGAL:CLN3* cells (effectively *bck2 cln3*) were released from the α -factor arrest, the levels of *CLN1*, *CLN2*, and *CLB5* RNA remained very low and the cells did not form a bud, even up to 72 min after the release (Fig. 2A). The *SWI4* RNA levels for the $\Delta bck2$ *pGAL:CLN3* cells increased, but not quite to the levels as for the *BCK2 pGAL:CLN3* cells. The very low *CLN1* and *CLN2* RNA accumulation in *bck2 cln3* cells, along with the finding that the long G_1 delay and the growth defect of *bck2 cln3* cells is cured by heterologous expression of *CLN2*, suggests that in the absence of *CLN3*, *BCK2* is most likely required for significant levels of *CLN1*, *CLN2*, and *CLB5* RNA accumulation. That the defect in *SWI4* RNA accumulation is relatively modest compared with the very strong defects in *CLN1* and *CLN2* RNA accumulation raises the possibility that *bck2 cln3* cells are defective in the ability of *SWI4* to stimulate *CLN1* and *CLN2* RNA accumulation (or alternatively in the expression of *SWI4* protein from *SWI4* RNA).

Effect of $\Delta bck2$ and high-copy-number *BCK2* in the presence of *CLN3*. In the presence of *CLN3*, deletion of *BCK2* does not result in any significant decrease in the growth rate of the cell (18, 24). However, the absence of *BCK2* caused a modest decrease in the accumulation rate (peak levels were delayed about 10 min) and a modest decrease in the peak levels of *CLN2* and *HCS26* RNAs during late G_1 (Fig. 2B). Therefore, like the loss of *CLN3* function in an otherwise wild-type strain, deletion of *BCK2* in an otherwise wild-type strain results in a modest decrease in the rate and levels of *CLN2* RNA accumulation. In contrast to the *CLN2* and *HCS26* RNA levels, the *SWI4* RNA levels are more similar (and have about a 5-min delay) in the $\Delta bck2$ strain compared with the wild-type strain, suggesting that the ability of *SWI4* to activate *CLN2* expression is partially defective in the absence of *BCK2*.

As a consequence of the alteration in *CLN1* and *CLN2* RNA accumulation, $\Delta cln3$ cells are more sensitive to α -factor and initiate Start at a larger than normal cell volume. Moreover, cells containing hyperactive alleles of *CLN3* are more resistant to α -factor and initiate Start at a smaller than normal cell volume (8, 29). Therefore, we determined the α -factor sensi-

FIG. 2. Effect of *BCK2* on *CLN1* and *CLN2* expression in the absence or presence of *CLN3*. (A) The absence of *CLN3*. Strains $\Delta Y79$ ($\Delta bck2$ *pGAL:CLN3* {YCP50}) and $\Delta Y80$ ($\Delta bck2$ *pGAL:CLN3* {BCK2/YCP50}) were grown exponentially at 30°C in SC-uracil 2% galactose medium to an OD_{600} of 0.08. The cells were arrested in G_1 by addition of α -factor (to a final concentration of 0.012 mM), which represses *CLN1* and *CLN2* expression. After 2.75 h with α -factor, the cells arrested in late G_1 by the criteria of budding index, DNA content (flow cytometry), and the presence of schmoos-shaped cells. Next, *CLN3* expression was repressed by addition of glucose to 2% (final concentration) (*CLN3* RNA and protein are unstable so that their levels decrease rapidly [9, 40]). After 0.5 h in glucose, the cells were released from the α -factor arrest by filtering, washing, and resuspending in fresh SC-uracil 2% glucose medium. All procedures were performed in parallel for the two cultures. (B) The presence of *CLN3*. Isogenic strains CY3317 (*BCK2*) and CY3319 ($\Delta bck2$) were grown exponentially in SC-uracil 2% glucose medium at 30°C to an OD_{600} of 0.22, at which time α -factor was added to 0.01 mM (final concentration). After 2.5 h, the cells were released (in parallel) from the α -factor arrest by filtering, washing, and resuspending in fresh SC-uracil 2% glucose medium. For both panels, total RNA was prepared from cells collected at the indicated times after the α -factor release; 5 μ g of total RNA was loaded onto each lane of a 1% agarose gel, and the Northern blots were prepared as described in Materials and Methods.

tivity and cell size of $\Delta bck2$, wild-type, and high-copy-number *BCK2* strains. The $\Delta bck2$ cells were more sensitive to α -factor, while high-copy-number *BCK2*-containing cells were more resistant to α -factor (Fig. 3A). The increased sensitivity of $\Delta bck2$ cells to α -factor was due to a defect in *CLN1* and *CLN2* RNA accumulation because expression of *CLN2* coding sequences from the *S.p.ADH* promoter restored normal α -factor sensitivity to the $\Delta bck2$ cells (data not shown). In addition, $\Delta bck2$ cells also had a larger than normal cell volume (confirming the findings of Epstein and Cross [18]), while high-copy-number *BCK2*-containing cells had a slightly smaller than normal cell volume (Fig. 3B). Together, these findings indicate that even in the presence of *CLN3*, *BCK2* has a role at Start.

Overexpression of *BCK2* stimulates the expression of *CLN1* and *CLN2*. The results presented above suggest that *BCK2* and *CLN3* provide parallel activation pathways for the expression of *CLN1* and *CLN2*. Moreover, the *BCK2* gene on a high-copy-

FIG. 3. Phenotypes due to the absence of BCK2 or the overexpression of BCK2. (A) α -Factor sensitivity. Equal numbers of exponentially growing cells (about 1,000 cells, grown in SC-uracil or SC-leucine 2% glucose medium) of strains CY3319 ($\Delta bck2$ {YCp50}), CY3317 and CY3318 ($\Delta bck2$ {*BCK2*/YCp50}), CY3321 ($\Delta bck2$ {YEp13}), and CY3320 ($\Delta bck2$ {*BCK2*/YEp13}) were spotted onto YPD plates containing the indicated concentration of α -factor. All of the strains are transformants of strain CY3276. The plates were incubated at 30°C for the indicated times. WT, wild type. (B) Cell size. Shown are Coulter Channelyzer plots (29) of cell volume distributions for cells growing exponentially in SC-uracil 2% glucose medium at 30°C. The strains were CY3319 ($\Delta bck2$ {YCp50}), CY3317 ($\Delta bck2$ {*BCK2*/YCp50}), and CY3368 ($\Delta bck2$ {*BCK2*/YEp24}). Strain CY3370 ($\Delta bck2$ {YEp24}) had a cell volume distribution indistinguishable from that of CY3319 ($\Delta bck2$ {YCp50}) (data not shown). All of the strains are transformants of CY3276.

number plasmid stimulated the growth rate of a *CLN1* $\Delta cln2$ $\Delta cln3$ strain (which has a moderate slow-growth phenotype due to lower than normal levels of G₁ cyclins [13]) and also stimulated the slow growth rate of a $\Delta swi4$ strain (the slow growth rate of $\Delta swi4$ strains is due to a defect in G₁ cyclin

TABLE 2. Summary of genetic interactions of *BCK2*

Strain	Growth rate	Plus high-copy-number <i>BCK2</i>	Plus $\Delta bck2$
$\Delta cln3$	wt ^a	ND ^b	Viable, but grows very slowly ^c
$\Delta cln1$	wt	ND	No effect
$\Delta cln2$	wt	ND	No effect
$\Delta cln1 \Delta cln2$	Near wt ^d	ND	Slightly slower than $\Delta cln1 \Delta cln2$
$\Delta cln2 \Delta cln3$	Moderate	Stimulates	ND
$\Delta swi4$	Slow	Stimulates	Much slower than $\Delta swi4$ alone ^e
$\Delta swi6$	Slow	No effect	Lethal ^f

^a wt, wild type.
^b ND, not determined.
^c Heterologous expression of *CLN2* from either the *S.p.ADH* or the *S.c.ADH* promoter stimulated the growth rate of *bck2 cln3* strains to near wild-type levels.
^d Both strains for this cross had *SSD1-v* genetic backgrounds because $\Delta cln1 \Delta cln2$ *CLN3 ssd1-d* strains grow very slowly (12).
^e Heterologous expression of *CLN2* from either the *S.p.ADH* or the *S.c.ADH* promoter stimulated the growth rate of *bck2 swi4* strains, but not quite to that of *swi4* strains.
^f Heterologous expression of *CLN2* from either the *S.p.ADH* or the *S.c.ADH* promoter cured the lethality of *bck2 swi6* strains, but the resulting strains did not grow as well as *swi6* strains.

expression; see reference 31) (Table 2). In contrast, the slow growth rate of a $\Delta swi6$ strain, which is not stimulated by low- or high-level heterologous expression of *CLN2* (data not shown), is not stimulated by the *BCK2* gene on a high-copy-number plasmid (Table 2).

To look directly at the ability of overexpressed BCK2 to activate transcription of *CLN1* and *CLN2*, we prepared Northern blots with RNA isolated from a strain containing *BCK2* coding sequences expressed from the *GAL1* promoter (see Materials and Methods). Twenty minutes after galactose was added to a p*GAL*:*BCK2* strain, the levels of *BCK2* RNA increased dramatically (Fig. 4A). The increase in *BCK2* levels subsequently (by 40 min) induced very high level expression of *CLN1* and *CLN2* (whose promoters contain SWI4/SWI6-dependent cell cycle box [SCB]-like and *MluI*-containing cell cycle box [MCB]-like elements [10, 31, 36]) and *CLB5* (whose promoter contains MCB-like elements [17]) (Fig. 4A). Transcription from SCB and MCB promoter elements is cell cycle dependent and reaches maximal levels during late G₁. The increase in *CLN1*, *CLN2*, and *CLB5* RNA levels by overexpressed BCK2 was not due to accumulation of the cells in G₁, as determined by the budding index and flow cytometry analysis of the cultures (data not shown). Interestingly, overexpression of BCK2 only slightly increased *SWI4* RNA levels in this strain (Fig. 4B and data not shown). Therefore, overexpression of BCK2 can induce high-level accumulation of *CLN1* and *CLN2* RNAs by a mechanism that does not require a large increase in *SWI4* transcription. Further demonstration of specificity in the ability of overexpressed BCK2 to induce high levels of a given cell cycle-regulated RNA is the finding that overexpressed BCK2 did not increase the levels of histone *HTA1* RNA (Fig. 4A).

Promoters containing multiple SCB or multiple MCB elements are activated about twofold by overexpression of BCK2. Overexpression of BCK2 could increase *CLN1* and *CLN2* RNA levels either by increasing the rate of transcription or by increasing the stability of the RNAs. Although overexpressed BCK2 greatly increased *CLN2* RNA levels when *CLN2* was expressed from the wild-type promoter, it had no effect when

FIG. 4. Overexpressed BCK2 can activate *CLN1*, *CLN2*, and *CLB5* transcription. (A) Strains CY3507 (*pGAL:BCK2*/YCp50) and CY3510 (YCp50/*pGAL* expression plasmid with no insert) were grown exponentially at 30°C on SC-uracil 2% raffinose medium. Both strains are transformants of strain AY925 (which contains a wild-type [WT] *BCK2* gene). At an OD₆₀₀ of 0.20, galactose was added to 2% (final concentration), and cells were collected at the indicated times. (B) Strains CY3507 and CY3510 were transformed with a *LEU2/cen* plasmid containing the *S.p.ADH:CLN2* gene. The *S.p.ADH:CLN2* gene gives a *CLN2* RNA shorter than the wild-type *CLN2* RNA because it is missing about 100 bases of 5' *CLN2* RNA sequences. The strains were grown exponentially at 30°C on SC-uracil-leucine 2% raffinose medium. At an OD₆₀₀ of 0.20, galactose was added to 2% (final concentration), and cells were collected at the indicated times. cont., control. For both panels, total RNA was prepared and Northern analysis was performed as described in Materials and Methods.

CLN2 was expressed from the *S.p.ADH* promoter (Fig. 4B). Therefore, sequences upstream of the *CLN2* start codon are required for induction by overexpressed BCK2.

In vitro, SWI4/SWI6 complexes are the major factors that bind to SCB elements, while MBP1/SWI6 complexes are the major factors that bind to MCB elements (1, 2, 14, 22, 26, 38). Recently, it has been shown that deletion of a 101-bp *NruI-SphI* restriction fragment from the *CLN2* promoter, which removes or destroys three SCB-like sequences and two CGCG core MCB-like sequences, causes a dramatic reduction in *CLN2* RNA levels (10, 36). We placed the *NruI-SphI* *CLN2* promoter fragment into the $\Delta 52$ -*HIS4:lacZ* reporter gene on YCp50 (28). The $\Delta 52$ mutation removes the *HIS4* upstream activating sequences so that this reporter, without an insert, gave 1 U of β -galactosidase activity, and *pGAL:BCK2* had no effect on these levels. In a control strain (no *pGAL:BCK2*), the reporter containing the *NruI-SphI* *CLN2* promoter fragment was not activated when galactose was added to the culture (Table 3). By contrast, in a *pGAL:BCK2* strain, the reporter containing the *NruI-SphI* *CLN2* promoter fragment was activated 1.74-fold when galactose was added to the culture (Table

TABLE 3. Overexpressed BCK2 can activate transcription from a *CLN2* promoter fragment^a

Strain	β -Galactosidase activity (U) ^b		Ratio ^c
	Raffinose	+ Galactose	
Control	53 (8.3)	52 (1)	0.98
<i>pGAL:BCK2</i>	46 (4.5)	80 (7.2)	1.74

^a All strains were transformants of AY925 that contained the $\Delta 52$ -*HIS4:lacZ*/YCp50 reporter plasmid (28) containing the *NruI-SphI* *CLN2* promoter fragment in the wild-type orientation and either a control plasmid or a *pGAL:BCK2* plasmid (*LEU2* marker). The reverse orientation of the *CLN2* promoter fragment gave 1.84-fold induction with *pGAL:BCK2* and 0.99-fold induction with the control plasmid. The transformants were grown exponentially at 30°C on SC-uracil-leucine 2% raffinose medium. At time zero, galactose was added to 2% (final concentration), and the cultures were grown for 4 h. Whole cell extracts were prepared and β -galactosidase assays were performed as described in Materials and Methods.

^b Standard deviations (from three or four independent assays) are in parentheses.

^c Units on galactose divided by units on raffinose.

3). These findings suggest that BCK2-responsive elements are at least partially within the *NruI-SphI* *CLN2* promoter fragment, which contains two intact SCB-like sequences and one intact CGCG core MCB-like sequence.

To assay transcription from only SCB promoter elements, we used a strain containing a *lacZ* reporter gene whose transcription was activated by four synthetic SCB elements (SCB sequence from the *HO* promoter [31]; strain provided by B. Andrews). Relative to the control vector with no insert, overexpression of SWI4 from the *pGAL* promoter greatly stimulated transcription from the multiple synthetic SCB elements (Fig. 5A). Overexpression of BCK2 also stimulated transcription from the multiple synthetic SCB elements, to levels slightly higher than those obtained from overexpression of CLN3-1 (which encodes a hyperactive form of CLN3) and modestly higher than those obtained from overexpression of wild-type CLN3 (by 4 h, *pGAL:CLN3* gives 75 U [data not shown]). Therefore, like overexpressed CLN3 or CLN3-1, overexpressed BCK2 can induce transcription from SCB elements.

Overexpressed BCK2 might activate transcription from the multiple synthetic SCB elements indirectly. For instance, overexpressed BCK2 might activate the expression of *CLN1* or *CLN2* via a non-SCB promoter element, and the higher levels of CLN1 and CLN2 would then activate transcription from the multiple synthetic SCB elements (the same argument is also possible for the activation of SCB elements by overexpressed CLN3). If overexpressed BCK2 activates *CLN1* or *CLN2* expression, which in turn activates SCB-driven transcription, then overexpression of CLN1 or CLN2 from the *pGAL* promoter should induce SCB-driven transcription. Neither *pGAL:CLN1* (Fig. 5A) nor *pGAL:CLN2* (data not shown) caused an increase in the β -galactosidase levels expressed from a *lacZ* gene whose transcription is driven by multiple synthetic SCB elements. Therefore, in this assay, overexpressed CLN3, but not CLN1 or CLN2, activated SCB-dependent transcription. These findings suggest that CLN1 and CLN2 are not nearly as effective as CLN3 for activating SCB-dependent transcription. In addition, we looked at the ability of overexpressed BCK2 to activate transcription from the multiple synthetic SCB elements in the absence of SWI4 or SWI6. Unlike transcription from the *CLN1* and *CLN2* promoters (which are transcribed at low levels in the absence of SWI4 [10, 31, 36]), transcription from the promoter containing multiple synthetic SCB elements is completely SWI4 dependent (in the presence of SWI6) or

FIG. 5. Overexpressed BCK2 can activate transcription from SCB and MCB promoter elements. (A to C) Strains CY3557 (wild type), CY3582 ($\Delta swi4$), and CY3656 ($\Delta swi6$) were isogenic and contained the *lacZ* gene under the control of four tandem synthetic SCB elements integrated at the *HIS3* locus, termed *his3 Δ 124lacZ* (31). These strains were transformed with the indicated *URA3/cen* pGAL expression plasmid. The transformants were grown exponentially at 30°C on SC-uracil 2% raffinose medium, and at time zero, galactose was added to 2% (final concentration). (D) Strains CY3798 (wild type [wt]) and CY3779 ($\Delta swi6$), both isogenic and containing a 2 μ m *URA3* plasmid with the *lacZ* gene under the control of four tandem synthetic MCB elements (41), were transformed with the indicated *LEU2/cen* pGAL expression plasmid. The transformants were grown exponentially at 30°C on SC-uracil-leucine 2% raffinose medium, and at time zero, galactose was added to 2% (final concentration). For all panels, extracts were prepared and β -galactosidase assays were performed as described in Materials and Methods.

SWI6 dependent (in the presence of SWI4) (Fig. 5B and C). Moreover, overexpression of BCK2 (or CLN3 or CLN3-1) cannot bypass the requirement of SWI4 or SWI6 for the activation of transcription from the multiple synthetic SCB elements (Fig. 5B and C) (overexpressed BCK2 did not give any induction of the low *SWI4*- or *SWI6*-independent expression of 1 U).

Because the *CLN1* and *CLN2* promoters also contain core MCB-like CGCG elements (SWI4 can bind in vitro to MCB elements [22]) and because overexpressed BCK2 was also able to stimulate the transcription of *CLB5* (whose promoter contains MCB-like elements [17]), we determined the ability of overexpressed BCK2 to stimulate transcription from a promoter containing four synthetic MCB elements (plasmid pBA487 in reference 41; provided by B. Andrews). Interestingly, overexpressed BCK2 stimulated expression from the multiple synthetic MCB elements, and this stimulation was completely dependent on SWI6 (Fig. 5D). Overexpression of *CLN2* (from the *GAL1* promoter) was not able to stimulate

MCB-dependent expression in this assay (data not shown). Therefore, the ability of overexpressed BCK2 to stimulate transcription from the multiple synthetic MCB elements is not due to the increased levels of *CLN2* RNA.

Roles of SWI4 and SWI6 in BCK2-induced transcription from promoters containing SCB-like and MCB-like elements.

In contrast to the promoter containing the multiple synthetic SCB elements (whose transcription is completely SWI4 or SWI6 dependent), the *CLN1* and *CLN2* promoters are expressed at low levels in the absence of SWI4 or in the absence of SWI6. Interestingly, some of the transcriptional activation of *CLN1*, *CLN2*, and *HCS26* (an additional cyclin whose promoter contains SWI4/SWI6 binding sites [31]) by overexpressed BCK2 was not dependent on SWI4 (in the presence of SWI6) or dependent on SWI6 (in the presence of SWI4). The fold induction by overexpressed BCK2 was similar for the $\Delta swi4$ or $\Delta swi6$ strain compared with the wild-type strain. However, overexpressed BCK2 induced *CLN1*, *CLN2*, and *HCS26* to higher levels in the presence of SWI4 and SWI6 (Fig. 6) (the

FIG. 6. Roles of SWI4 and SWI6 in BCK2-induced transcription. Isogenic strains CY3574 (wild type [WT]), YCp50/pGAL expression plasmid with no insert), CY3575 (wild type, pGAL:BCK2/YCp50), CY3594 ($\Delta swi4$, YCp50/pGAL expression plasmid with no insert), CY3595 ($\Delta swi4$, pGAL:BCK2/YCp50), CY3671 ($\Delta swi6$, YCp50/pGAL expression plasmid with no insert), and CY3672 ($\Delta swi6$, pGAL:BCK2/YCp50) were grown exponentially at 30°C on SC-uracil 2% raffinose medium. Strains CY3574 and CY3575 are transformants of CY3557, strains CY3594 and CY3595 are transformants of CY3582, and strains CY3671 and CY3672 are transformants of CY3656. At an OD₆₀₀ of 0.20, galactose was added to 2% (final concentration), and the cells were collected at the indicated times. Total RNA was prepared and Northern analysis was performed as described in Materials and Methods. Because the gel only had 20 lanes, identical $\Delta swi4$ samples were loaded onto two separate gels, so that the RNA levels of the $\Delta swi6$ cells can be directly compared with those in the $\Delta swi4$ cells and, by comparison with the other gel, with those in the wild-type cells. Like *ACT1*, the *URA3* RNA lengths and levels were not affected by overexpression of BCK2 (data not shown).

level of induction of the *GAL1* promoter is not as high for the isogenic wild-type, $\Delta swi4$, and $\Delta swi6$ strains used for Fig. 5 and 6 as for the strains used in Fig. 4; note also that the level of *CLN2* induction was lower for the strains in Fig. 6 than for those in Fig. 4).

Therefore, although maximal stimulation of *CLN1* and *CLN2* transcription by overexpressed BCK2 required SWI4 or SWI6, some of the overexpressed BCK2-induced levels of *CLN1* and *CLN2* RNA resulted from either a promoter element that is normally SWI4 or SWI6 independent (an element

unrelated to SCB or MCB elements to which SWI4 and SWI6 would not interact) or from a SWI4- or SWI6-independent mode of activation through promoter elements that are normally largely SWI4 or SWI6 dependent (such as SCB- or MCB-like elements). If the stimulation of *CLN1* and *CLN2* expression by overexpressed BCK2 is due to promoter elements that are normally largely SWI4 or SWI6 dependent, overexpressed BCK2 would have to function differently at the natural *CLN1* and *CLN2* SCB-like and MCB-like elements compared with the multiple synthetic SCB and MCB elements (where activation by overexpressed BCK2 is completely SWI4 or SWI6 dependent [Fig. 5]).

Overexpression of BCK2 in wild-type strains also stimulated *CLB5* expression and *RNR1* (16) expression, and this stimulation was completely independent of *SWI4* (Fig. 4, Fig. 6, and data not shown). Both the *CLB5* promoter (17) and the *RNR1* promoter (15a) contain multiple MCB-like sequences. Normal periodic transcription of certain MCB-driven genes requires both MBP1 and SWI6 (14, 22, 25, 27). MBP1 is a SWI4-related transcription factor that binds, in a complex with SWI6, to MCB promoter elements (22). In a $\Delta swi6$ strain, the normal length *RNR1* RNA is reduced in abundance, while a longer *RNR1* RNA is present (Fig. 6) (because this length change is small, we include two panels for *RNR1*, each from a different gel). This effect of a *swi6* mutation on *RNR1* RNA has been seen previously (14). Importantly, overexpression of BCK2 stimulated *RNR1* expression in the absence of *SWI6*, and this BCK2-induced *RNR1* RNA had a normal or very near normal length (Fig. 6). This *SWI6*-independent stimulation of *RNR1* transcription is not due to the ability of overexpressed BCK2 to stimulate *MBP1* RNA levels (Fig. 6) (in these cultures, the overall *MBP1* RNA levels are independent of *SWI4* or *SWI6* [Fig. 6] and do not vary in the cell cycle [22]).

We also determined the effect of overexpressed BCK2 on *CLB2* expression. *CLB2*, which encodes a B-type cyclin, is expressed during S and G₂ phases (20, 32). Overexpression of BCK2 increased *CLB2* RNA levels in a wild-type strain (Fig. 6). The levels of *CLB2* RNA were low for the $\Delta swi4$ cells, possibly because the culture is enriched in G₁ cells as a result of the defect in *CLN1* and *CLN2* expression. Interestingly, overexpression of BCK2 in a $\Delta swi4$ strain or a $\Delta swi6$ strain (but not a wild-type strain) stimulated the expression of a shorter *CLB2* RNA (Fig. 6). The nature of the *CLB2* promoter element responsible for this effect is not known.

For the *CLN2* promoter, the UAS2 region is required for maximal induction by overexpressed BCK2. Overexpressed BCK2 caused about a twofold activation of transcription from the *CLN2* *NruI*-*SphI* promoter fragment, which contains two intact SCB-like sequences and one intact CGCG core MCB-like sequence (Table 3). This fold activation is similar to the approximately twofold activation of multiple synthetic SCB or MCB elements by overexpressed BCK2 (Fig. 5). By contrast, for the chromosomal *CLN1* and *CLN2* genes in the W303 strain background (Fig. 4A), overexpressed BCK2 increased the RNA levels much more than twofold.

To determine the *CLN2* promoter sequences that are responsible for this greater activation by overexpressed BCK2, we prepared *CLN2* promoter deletions (Fig. 7A). The *CLN2-AA* gene lacks sequences upstream of the *NruI* site, which removes or destroys potential MCB CGCG core elements at -644 and -603 and the SCB-like element at -603. Compared with the chromosomal *CLN2* gene, *CLN2-AA* on the *LEU2/cen* plasmid gave about twofold-lower levels of *CLN2* RNA when BCK2 was overexpressed (Fig. 7B and data not shown). When UAS1 was also absent (*CLN2-BB*), the level of *CLN2* expression was extremely low and was no longer

FIG. 7. *CLN2* promoter sequences required for activation by overexpressed BCK2. (A) The *CLN2* promoter sequences present in each deletion (see Materials and Methods) are indicated by a horizontal line. All numbers are relative to the A of the predicted *CLN2* ATG initiation codon. UAS1 and UAS2 of Stuart and Wittenberg (36) are shown. The *NruI* site is at position -601, and the *SphI* site is at position -505. For the three indicated SCB-like elements, the element at position -603 has a 6-of-8-bp (6/8), the element at position -578 has a 7/8, and the element at position -526 has a 7/8 match to the *HO* consensus SCB sequence CACGAAAA. However, additional possible SCB-like sequences with a 6/8 match to the SCB consensus sequence are present in the *CLN2* promoter (forward orientation 6/8 sequences occur at positions -621, -615, -526, -361, and -355, while reverse orientation 6/8 sequences occur at positions -471, -403, and -302). (B) In the absence of sequences upstream of the *SphI* site (-505), *CLN2* RNA levels are extremely low and are not induced by overexpressed BCK2. The wild-type (WT) chromosomal *CLN2* strain (CY3507) was grown on SC-uracil 2% raffinose medium. The strains containing *CLN2* expressed from promoters AA or BB (in either orientation on a *LEU2/cen* plasmid; see Materials and Methods) are isogenic to CY3507 except that they also have a near complete deletion of chromosomal *CLN2* coding sequences (CY4271). The strains containing *CLN2* expressed from the AA or BB promoters were grown on SC-uracil-leucine 2% raffinose medium. Cells, grown at 30°C, were collected just prior to (-) or 55 min after (+) the addition of galactose to 2% (final concentration). The *CLN2* RNAs expressed from the *CLN2* AA and BB promoters are slightly longer than wild-type *CLN2* RNA because the *CLN2* promoter deletions were prepared by using a *CLN2* gene with sequences encoding a triple hemagglutinin epitope tag at the carboxyl terminus (*CLN2C* in reference 39). The *CLN2* panel is overexposed to show the very low levels of *CLN2* RNA expressed from the BB promoter. (C) The UAS2 region is required for maximal activation of *CLN2* by overexpressed BCK2. *CLN2* was expressed from promoter AA, CC, DD, or EE (on a *LEU2/cen* plasmid) in strain CY4271. The strains were grown at 30°C in SC-uracil-leucine 2% raffinose medium. Cells were collected just prior to (-) or 55 min after (+) the addition of galactose to 2% (final concentration).

increased by overexpressed BCK2 (Fig. 7B). Therefore, activation of *CLN2* transcription by overexpressed BCK2 requires promoter elements within UAS1 (probably the SCB-like and MCB-like sequences). Also, UAS2 (36) by itself is not sufficient for activation by overexpressed BCK2.

We also determined if UAS2 sequences or other sequences

FIG. 8. Genetic interactions of *BCK2* with *SIT4* and *MPK1*. (A) Low- or high-level heterologous expression of *CLN2* does not cure the temperature-sensitive phenotype of a *Δmpk1* strain. Strain CY3182 (*Δmpk1*) was transformed with the indicated plasmids. Transformants were patched onto SC-uracil 2% glucose plates, grown for 1 day at 24°C, and replica plated onto YEP24 plates. Growth is shown after 1.5 days at 37°C. (B) Unlike *Δcln3 Δsit4 SSD1-v* strains, which are nearly inviable, *Δbck2 Δsit4 SSD1-v* strains grow at the same rate as *Δsit4 SSD1-v* strains. Strain CY3276 (*Δbck2 SSD1-v*) was crossed to strain CY279 (*Δsit4 SSD1-v*), and representative progeny (from 20 tetrads) of the indicated genotype were streaked onto YEP24 plates. Growth is shown after 4.5 days at 30°C. WT, wild type. (C) A model of *BCK2* function relative to that of *CLN3* and *SIT4*. The placement of *SIT4* upstream of *BCK2* is arbitrary.

downstream of UAS1 could modulate the ability of BCK2 to induce transcription from UAS1. The activation of *CLN2-DD* and *CLN2-EE* transcription by overexpressed BCK2 was similar to that of *CLN2-AA* (Fig. 7C). By contrast, the absence of UAS2 sequences (*CLN2-CC*) caused a substantial reduction in the ability of overexpressed BCK2 to induce *CLN2* transcription (Fig. 7C). Therefore, sequences contained in the UAS2 region are required for maximal induction of *CLN2* transcription by overexpressed BCK2.

Relationship of *BCK2* to *PKC1* and *MPK1*. The *BCK2* gene was originally isolated by its ability, when present on a high-copy-number plasmid, to suppress the temperature-sensitive phenotype of a *Δmpk1* strain (24). *MPK1* encodes a mitogen-activated protein kinase homolog that functions downstream of the protein kinase C homolog encoded by the *PKC1* gene. That overexpression of BCK2 stimulated *CLN1* and *CLN2* expression raised the possibility that the suppression of a *Δmpk1* strain by BCK2 was due to the ability of BCK2 to stimulate G₁ cyclin expression. Although the *BCK2* gene on a high-copy-number plasmid suppressed, neither normal-level (*S.p.ADH:CLN2*) or high-level (*S.c.ADH:CLN2*) heterologous expression of *CLN2* (Fig. 8A) nor high-copy-number *MBP1* (data not shown) suppressed the temperature-sensitive phenotype of the *Δmpk1* strain. We suggest that high-copy-number BCK2 suppresses a *Δmpk1* strain by stimulating the expression of some gene(s) other than *CLN1* and *CLN2*. In addition, although high-copy-number BCK2 partially suppressed the temperature-sensitive phenotype of an *mpk1* strain (and also partially suppressed the slow-growth-rate phenotype at 24°C), neither *CLN3* nor *CLN3-1* on a high-copy-number plasmid suppressed the *Δmpk1* strain (data not shown). Therefore,

although BCK2 and CLN3 can each separately activate *CLN1* and *CLN2* transcription, only BCK2 would be able to stimulate the transcription of the putative gene(s) that suppresses the defects of an *mpk1* strain.

Relationship of BCK2 to SIT4. We isolated mutations that result in lethality or cause a very slow growth rate in the absence of *CLN3* in order to obtain genes that function in the *SIT4* pathway for the activation of *CLN1* and *CLN2* expression. The absence of both the *SIT4* pathway and the *CLN3* pathway for the activation of *CLN1* and *CLN2* expression results in an extremely slow-growth phenotype (7 days for a *sit4 cln3* strain to form microcolonies) that is due to a defect in *CLN1* and *CLN2* expression (the synthetic growth defect is completely cured by heterologous expression of *CLN2* from the *S.p.ADH* promoter) (19). The absence of both the *BCK2* pathway and *CLN3* pathway for the activation of *CLN1* and *CLN2* expression also results in a slow-growth phenotype that is due to a defect in *CLN1* and *CLN2* expression. If *BCK2* functions within the *SIT4* pathway for the activation of *CLN1* and *CLN2* expression, then a $\Delta bck2 \Delta sit4$ strain should not grow any more slowly than a $\Delta sit4$ strain (viability of $\Delta sit4$ strains requires *SSD1-v* genetic backgrounds [19, 37]). If, like *CLN3*, *BCK2* functions in a pathway parallel to *SIT4* for the activation of *CLN1* and *CLN2* expression, then a $\Delta bck2 \Delta sit4$ strain (like a $\Delta cln3 \Delta sit4$ strain) should grow much more slowly than a $\Delta sit4$ strain. From a cross of a $\Delta bck2$ strain to a $\Delta sit4$ strain, the $\Delta bck2 \Delta sit4$ progeny grew at the same rate as the $\Delta sit4$ progeny (Fig. 8B). This finding suggests that BCK2 and CLN3 activate *CLN1* and *CLN2* expression by different pathways and that BCK2 may function within the *SIT4* pathway for the activation of *CLN1* and *CLN2* expression (Fig. 8C). Consistent with this model is the finding that, like a $\Delta sit4 \Delta swi6$ strain which is inviable (19), a $\Delta bck2 \Delta swi6$ strain is also inviable (Table 2). Because a $\Delta sit4$ strain accumulates *CLN1* and *CLN2* RNA at a rate much slower than that of a $\Delta bck2$ strain, the pathway proposed in this model cannot be linear but must include factors in addition to BCK2 within the *SIT4* pathway.

DISCUSSION

Cells containing a deletion of either the *BCK2* gene or the *CLN3* gene have a modest defect in *CLN1* and *CLN2* expression that causes the cells to be more sensitive to α -factor and to execute Start at a larger than normal cell volume. Therefore, BCK2 and CLN3 have similar effects on Start regulation. The defect in *CLN1* and *CLN2* expression in the absence of either BCK2 or CLN3 is modest: the cells have a wild-type growth rate, and the levels of *CLN1* and *CLN2* RNA increase to near normal levels during late G₁, but with a modest delay. Therefore, in the absence of CLN3, BCK2 (*BCK2* RNA levels do not vary in the cell cycle [12a]) can effectively activate the periodic expression of *CLN1* and *CLN2* during late G₁. Likewise, in the absence of BCK2, CLN3 (*CLN3* RNA levels vary two- to threefold during the cell cycle [19]) can effectively activate the periodic expression of *CLN1* and *CLN2* during late G₁. However, in the absence of both BCK2 and CLN3, the cells cannot effectively accumulate *CLN1* and *CLN2* RNAs during late G₁. This defect in *CLN1* and *CLN2* RNA expression is so severe that it causes $\Delta bck2 \Delta cln3$ cells to have a slow growth rate.

In contrast to $\Delta bck2 \Delta cln3$ cells, $\Delta bck2 \Delta cln1$ cells and $\Delta bck2 \Delta cln2$ cells grow at about the same rate as wild-type strains (reference 18 and Table 2). Moreover, $\Delta bck2 \Delta cln1 \Delta cln2$ strains grow only slightly more slowly than $\Delta cln1 \Delta cln2$ strains (Table 2). Although a cell is viable if it has any one of the three *CLN* genes (*CLN1*, *CLN2*, or *CLN3*) (33), the *CLN* genes are not equivalent. Unlike *CLN3*, the normal expression

of *CLN1* and *CLN2* requires *SWI4*, *SWI6*, and *SIT4* (19, 30, 31). Moreover, CLN3 has been proposed to be a regulator of Start via its effects on the accumulation of *CLN1* and *CLN2* RNA levels (39). Whether or not CLN3 can mediate Start directly (in which case the CLN3/CDC28 complex would phosphorylate the same Start substrates as the CLN1/CDC28 and CLN2/CDC28 complexes) is not currently known.

There are two possible explanations for the near normal growth rate of *bck2 cln1 cln2* cells in contrast to the very slow growth rate of *bck2 cln3* cells. For the first explanation, CLN3 can directly activate Start. In this case, in the absence of *CLN1*, *CLN2*, and *BCK2* (BCK2 is not required for *CLN3* expression [data not shown]), CLN3 would mediate the direct activation of Start. For the other explanation, CLN3 cannot directly activate Start but is a regulator of the expression of *CLN1*, *CLN2*, and other G₁ cyclins that are the direct activators of Start (39). In this case, CLN3, compared with CLN1 and CLN2, would be a much more potent activator of the expression of *CLN1* and *CLN2* and other G₁ cyclins. In the absence of the BCK2 activation pathway, CLN3 becomes almost essential for activating the expression of *CLN1*, *CLN2*, and other G₁ cyclin genes.

The late G₁ activation of *CLN1* and *CLN2* expression is due to multiple pathways. The major pathway for the activation of the *CLN1* and *CLN2* promoters is via SWI4 (10, 31, 36). SWI4 most likely binds to SCB-like and possibly MCB-like elements in the *CLN1* and *CLN2* promoters (22, 31). Because the great majority of *CLN1* and *CLN2* transcription is SWI4 dependent, BCK2 (at normal levels) is required in the absence of CLN3 for the SWI4-dependent activation of *CLN1* and *CLN2* transcription during late G₁.

Another way to assay the function of BCK2 is via the effects due to its overexpression. Overexpression of BCK2 greatly stimulates *CLN1*, *CLN2*, and *HCS26* expression (the extent of *CLN2* induction is strain dependent; compare Fig. 4 and 6). Overexpressed BCK2 also stimulates *CLB5*, *RNR1*, *SWI4*, and *CLB2* expression, but to a lesser extent. For these genes, a large fraction of the BCK2-induced RNA levels is dependent on either SWI4 or SWI6. However, in the absence of SWI4 (in the presence of SWI6) or in the absence of SWI6 (in the presence of SWI4), overexpression of BCK2 is still able to increase the levels of *CLN1*, *CLN2*, and *HCS26* RNAs, suggesting that BCK2 can also induce *CLN1*, *CLN2*, and *HCS26* transcription by a SWI4-independent mechanism (in the presence of SWI6) or by a SWI6-independent mechanism (in the presence of SWI4).

Unlike the reporter gene containing multiple synthetic SCB elements (whose expression is completely SWI4-dependent and cannot be induced by overexpressed BCK2 in the absence of SWI4), *CLN1* and *CLN2* have SWI4-independent pathways of transcriptional activation (they are transcribed at low levels in the absence of SWI4 [references 10 and 36 and Fig. 6]). It has been reported that the SWI4-independent expression of *CLN2* is dependent on MBP1, that MBP1 can bind in vitro to SCB elements, and that SWI4 can bind in vitro to MCB elements (22). MBP1 might be able to activate *CLN1* and *CLN2* transcription via the SCB-like or MCB-like elements present in these promoters (but MBP1 cannot activate transcription from the promoter containing multiple synthetic SCB elements). One possibility is that the ability of overexpressed BCK2 to stimulate *CLN1*, *CLN2*, and *HCS26* transcription in the absence of SWI4 (but to lower levels than when SWI4 is present) is due to the ability of BCK2 to stimulate MBP1-dependent activation from the SCB-like and/or MCB-like elements present in these promoters. Alternatively, overexpressed BCK2 might be able to stimulate *CLN1* and *CLN2* transcription via two different types of promoter elements; one type

would be an SCB- or MCB-like SWI4/SWI6/MBP1-dependent element, and a second type would be a non-SCB/MCB-related element (which would be present in the *CLN1*, *CLN2*, and *HCS26* promoters).

A large fraction of the expression of *CLN1* and *CLN2* during late G₁ is dependent on SWI4 and, for *CLN2*, requires the SCB-like and/or MCB-like elements present in the *CLN2* promoter (10, 30, 31, 36). Therefore, in the absence of CLN3, normal levels of BCK2 are required for the SWI4-dependent expression of *CLN1* and *CLN2*, possibly for regulating SWI4's ability to activate transcription via SCB-like and/or MCB-like elements. The large activation of *CLN2* transcription by overexpressed BCK2 seems to be due to two pathways; one pathway is the about twofold induction inherent within UAS1 (probably via the SCB- and MCB-like elements), a second pathway is via the ability of UAS2 to modulate activation by UAS1. It is not known if the sequences within UAS2 through which BCK2 modulates activation by UAS1 are the same sequences that give UAS2 the ability, by itself, to very weakly activate transcription during late G₁ (36).

Overexpression of BCK2 also stimulates the transcription of *CLB5* and *RNR1*, two genes suggested to be activated by MCB-like elements, and the transcription of a promoter containing multiple synthetic MCB elements. In vitro, the major binding activity to MCB elements is due to MBP1/SWI6 complexes (22). In a *Δswi6* strain, in which the normal length *RNR1* RNA is reduced in abundance while a lower amount of a longer *RNR1* RNA is present, overexpression of BCK2 stimulates the transcription of the normal- or near-normal-length *RNR1* RNA. Therefore, at the *RNR1* promoter, overexpressed BCK2 can substitute for the function of SWI6. A model whereby BCK2 would regulate the function of both SWI4- and MBP1-containing complexes to modulate transcription at SCB-like and MCB-like elements is consistent with our findings. However, BCK2 may also be able to activate transcription from sequences other than SCB/MCB-like elements. The effect of overexpressed BCK2 on *CLB2* expression in the absence of SWI4 or SWI6 cannot be interpreted within this model until more is known about the factors that regulate the periodic transcription of *CLB2*. Interestingly, although the *CLB2* promoter region does not contain apparent SCB elements, it does contain two CGCG core MCB-like sequences at -827 and -660.

BCK2 has been isolated previously by two different suppression schemes. In one scheme, high-copy-number *BCK2* was isolated by its ability to suppress the temperature-sensitive phenotype of a *Δmpk1* strain (24). Because low- or high-level heterologous expression of *CLN2* did not cure the temperature-sensitive phenotype of the *Δmpk1* strain, we suggest that overexpression of BCK2 suppresses the temperature-sensitive phenotype of a *Δmpk1* strain by stimulating the expression of some gene(s), other than G₁ cyclin genes, whose expression is defective in the absence of MPK1 or whose increased expression can bypass MPK1 function.

BCK2 was also isolated by its ability, on low- or high-copy-number plasmids, to suppress the lethality due to the absence of *CLN1*, *CLN2*, and *CLN3* function (18, 20a). One possibility is that overexpressed BCK2 can activate the expression of additional cyclins (such as HCS26) that can substitute for the function of CLN1, CLN2, and CLN3. Alternatively, because overexpressed BCK2 can stimulate the expression of two different MCB-driven genes (*CLB5* and *RNR1*) and the expression driven by multiple synthetic MCB elements, overexpressed BCK2 might be able to bypass *CLN* function for the activation of MCB-driven genes.

We isolated *bck2* mutations because BCK2 is required for

significant *CLN1* and *CLN2* transcription in the absence of CLN3. The accumulation of *CLN1* and *CLN2* RNA during late G₁ probably functions as an integrator of growth and mating signals from various sources. Proteins such as FAR1 are induced by the α-factor pathway to repress the accumulation of CLN1 and CLN2 (6, 7). Because the CLN3 protein is very low in abundance and is unstable (9, 40), the levels of CLN3 might reflect the rate of protein synthesis. As such, CLN3 could set the rate of *CLN1* and *CLN2* RNA accumulation, and hence the timing of Start, relative to the rate of protein synthesis (39). Like CLN3, BCK2 can also activate *CLN1* and *CLN2* expression, and the importance of BCK2 for Start is uncovered when the cells lack the CLN3 activation pathway. It remains to be determined what growth signals, if any, regulate the ability of BCK2 to stimulate G₁ cyclin accumulation.

ACKNOWLEDGMENTS

We thank D. Levin for the *Δbck2* strain, B. Futcher for his original high-copy-number *BCK2*-containing plasmid, B. Andrews and J. Ogas for strains, T. Zhong for preparation of strains CY2446 and CY2932, J. Duffy, M. Ockler, and P. Renna for figure preparation and photography, members of the Arndt and Futcher laboratories for discussion, and B. Futcher, A. Sutton, and T. Zhong for comments on the manuscript.

This research was supported by NIH grant GM45179 to K.T.A.

REFERENCES

- Andrews, B. J., and I. Herskowitz. 1989. Identification of a DNA binding factor involved in cell-cycle control of the yeast *HO* gene. *Cell* **57**:21–29.
- Andrews, B. J., and I. Herskowitz. 1989. The yeast SWI4 protein contains a motif present in developmental regulators and is part of a complex involved in cell-cycle-dependent transcription. *Nature* (London) **342**:830–833.
- Andrews, B. J., and L. A. Moore. 1992. Interaction of the yeast Swi4 and Swi6 cell cycle regulatory proteins *in vitro*. *Proc. Natl. Acad. Sci. USA* **89**:11852–11856.
- Arndt, K. T. Unpublished data.
- Boeke, J. D., J. Trueheart, G. Natsoulis, and G. R. Fink. 1987. 5-Fluoroorotic acid as a selective agent in yeast molecular genetics. *Methods Enzymol.* **154**:164–175.
- Breedon, L., and G. E. Mikesell. 1991. Cell cycle-specific expression of the SWI4 transcription factor is required for the cell cycle regulation of *HO* transcription. *Genes Dev.* **5**:1183–1190.
- Chang, F., and I. Herskowitz. 1990. Identification of a gene necessary for cell cycle arrest by a negative growth factor of yeast: FAR1 is an inhibitor of a G1 cyclin, CLN2. *Cell* **63**:999–1011.
- Chang, F., and I. Herskowitz. 1992. Phosphorylation of FAR1 in response to alpha-factor: a possible requirement for cell-cycle arrest. *Mol. Biol. Cell* **3**:445–450.
- Cross, F. R. 1988. *DAF1*, a mutant gene affecting size control, pheromone arrest, and cell cycle kinetics of *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* **8**:4675–4684.
- Cross, F. R., and C. M. Blake. 1993. The yeast Cln3 protein is an unstable activator of Cdc28. *Mol. Cell. Biol.* **13**:3266–3271.
- Cross, F. R., M. Hoek, J. D. McKinney, and A. H. Tinkelenberg. 1994. Role of Swi4 in cell cycle regulation of *CLN2* expression. *Mol. Cell. Biol.* **14**:4779–4787.
- Cross, F. R., and A. H. Tinkelenberg. 1991. A potential positive feedback loop controlling *CLN1* and *CLN2* gene expression at the start of the yeast cell cycle. *Cell* **65**:875–883.
- Cvrckova, F., and K. Nasmyth. 1993. Yeast G1 cyclins CLN1 and CLN2 and a GAP-like protein have a role in bud formation. *EMBO J.* **12**:5277–5286.
- Di Como, C. J., and K. T. Arndt. Unpublished data.
- Di Como, C. J., R. Bose, and K. T. Arndt. 1995. Overexpression of SIS2, which contains an extremely acidic region, increases the expression of *SWI4*, *CLN1*, and *CLN2* in *sit4* mutants. *Genetics* **139**:95–107.
- Dirick, L., T. Moll, H. Auer, and K. Nasmyth. 1992. A central role for SWI6 in modulating cell cycle Start-specific transcription in yeast. *Nature* (London) **357**:508–513.
- Dirick, L., and K. Nasmyth. 1991. Positive feedback in the activation of G1 cyclins in yeast. *Nature* (London) **351**:754–757.
- Elledge, S. Personal communication.
- Elledge, S. J., and R. W. Davis. 1990. Two genes differentially regulated in the cell cycle and by DNA-damaging agents encode alternative regulatory subunits of ribonucleotide reductase. *Genes Dev.* **4**:740–751.
- Epstein, C. B., and F. R. Cross. 1992. CLB5: a novel B cyclin from budding yeast with a role in S phase. *Genes Dev.* **6**:1695–1706.

18. Epstein, C. B., and F. R. Cross. 1994. Genes that can bypass the CLN requirement for *Saccharomyces cerevisiae* cell cycle START. *Mol. Cell. Biol.* **14**:2041–2047.
19. Fernandez-Sarabia, M. J., A. Sutton, T. Zhong, and K. T. Arndt. 1992. SIT4 protein phosphatase is required for the normal accumulation of *SWI4*, *CLN1*, *CLN2*, and *HCS26* RNAs during late G1. *Genes Dev.* **6**:2417–2428.
20. Fitch, I., C. Dahmann, U. Surana, A. Amon, K. Nasmyth, L. Goetsch, B. Byers, and B. Futcher. 1992. Characterization of four B-type cyclin genes of the budding yeast *Saccharomyces cerevisiae*. *Mol. Biol. Cell* **3**:805–818.
- 20a. Futcher, B. Personal communication.
21. Hadwiger, J. A., C. Wittenberg, H. E. Richardson, M. de Barros Lopes, and S. I. Reed. 1989. A family of cyclin homologs that control the G1 phase in yeast. *Proc. Natl. Acad. Sci. USA* **86**:6255–6259.
22. Koch, C., T. Moll, M. Neuberg, H. Ahorn, and K. Nasmyth. 1993. A role for the transcription factors Mbp1 and Swi4 in progression from G1 to S phase. *Science* **261**:1551–1557.
23. Kranz, J. E., and C. Holm. 1990. Cloning by function: an alternative approach for identifying yeast homologs of genes from other organisms. *Proc. Natl. Acad. Sci. USA* **87**:6629–6633.
24. Lee, K. S., L. K. Hines, and D. E. Levin. 1993. A pair of functionally redundant yeast genes (*PPZ1* and *PPZ2*) encoding type 1-related protein phosphatases function within the PKC1-mediated pathway. *Mol. Cell. Biol.* **13**:5843–5853.
25. Lowndes, N. F., A. L. Johnson, L. Breeden, and L. H. Johnston. 1992. SWI6 protein is required for transcription of the periodically expressed DNA synthesis genes in budding yeast. *Nature (London)* **357**:505–508.
26. Lowndes, N. F., A. L. Johnson, and L. H. Johnston. 1991. Coordination of expression of DNA synthesis genes in budding yeast by a cell-cycle regulated trans factor. *Nature (London)* **350**:247–250.
27. Moll, T., L. Dirick, H. Auer, J. Bonkovsky, and K. Nasmyth. 1992. SWI6 is a regulatory subunit of two different cell cycle START-dependent transcription factors in *Saccharomyces cerevisiae*. *J. Cell Sci. Suppl.* **16**:87–96.
28. Nagawa, F., and G. R. Fink. 1985. The relationship between the “TATA” sequence and transcription initiation sites at the *HIS4* gene of *Saccharomyces cerevisiae*. *Proc. Natl. Acad. Sci. USA* **82**:8557–8561.
29. Nash, R., G. Tokiwa, S. Anand, K. Erickson, and A. B. Futcher. 1988. The *WHI1*⁺ gene of *Saccharomyces cerevisiae* tethers cell division to cell size and is a cyclin homolog. *EMBO J.* **7**:4335–4346.
30. Nasmyth, K., and L. Dirick. 1991. The role of SWI4 and SWI6 in the activity of G1 cyclins in yeast. *Cell* **66**:995–1013.
31. Ogas, J., B. J. Andrews, and I. Herskowitz. 1991. Transcriptional activation of *CLN1*, *CLN2*, and a putative new G1 cyclin (*HCS26*) by SWI4, a positive regulator of G1-specific transcription. *Cell* **66**:1015–1026.
32. Richardson, H., D. J. Lew, M. Henze, K. Sugimoto, and S. I. Reed. 1992. Cyclin-B homologs in *Saccharomyces cerevisiae* function in S phase and in G2. *Genes Dev.* **6**:2021–2034.
33. Richardson, H. E., C. Wittenberg, F. Cross, and S. I. Reed. 1989. An essential G1 function for cyclin-like proteins in yeast. *Cell* **59**:1127–1133.
34. Rose, M. D., P. Novick, J. H. Thomas, D. Botstein, and G. R. Fink. 1987. A *Saccharomyces cerevisiae* genomic plasmid bank based on a centromere-containing shuttle vector. *Gene* **60**:237–243.
35. Rose, M. D., F. Winston, and P. Hieter. 1990. Methods in yeast genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
36. Stuart, D., and C. Wittenberg. 1994. Cell cycle-dependent transcription of *CLN2* is conferred by multiple distinct *cis*-acting regulatory elements. *Mol. Cell. Biol.* **14**:4788–4801.
37. Sutton, A., D. Immanuel, and K. T. Arndt. 1991. The SIT4 protein phosphatase functions in late G1 for progression into S phase. *Mol. Cell. Biol.* **11**:2133–2148.
38. Taba, M. R., I. Muroff, D. Lydall, G. Tebb, and K. Nasmyth. 1991. Changes in a SWI4,6-DNA-binding complex occur at the time of *HO* gene activation in yeast. *Genes Dev.* **5**:2000–2013.
39. Tyers, M., G. Tokiwa, and B. Futcher. 1993. Comparison of the *Saccharomyces cerevisiae* G1 cyclins: Cln3 may be an upstream activator of Cln1, Cln2 and other cyclins. *EMBO J.* **12**:1955–1968.
40. Tyers, M., G. Tokiwa, R. Nash, and B. Futcher. 1992. The Cln3-Cdc28 kinase complex of *S. cerevisiae* is regulated by proteolysis and phosphorylation. *EMBO J.* **11**:1773–1784.
41. Verma, R., J. Smiley, B. Andrews, and J. L. Campbell. 1992. Regulation of the yeast DNA replication genes through the Mlu I cell cycle box is dependent on SWI6. *Proc. Natl. Acad. Sci. USA* **89**:9479–9483.
42. Wittenberg, C., K. Sugimoto, and S. I. Reed. 1990. G1-specific cyclins of *S. cerevisiae*: cell cycle periodicity, regulation by mating pheromone, and association with the p34^{CDC28} protein kinase. *Cell* **62**:225–237.